Erschienen in:
01.11.2015 | Commentary
The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma
verfasst von:
Jian-Hong Zhong
Erschienen in:
Tumor Biology
|
Ausgabe 11/2015
Einloggen, um Zugang zu erhalten
Excerpt
China is a region with high prevalence of hepatocellular carcinoma (HCC) [
1]. With improvements in surgical technique and perioperative care, hepatic resection is the first-line therapy for many patients in early HCC as well as intermediate or advanced disease [
2,
3]. However, tumor recurrence is common and jeopardizes patients’ prognosis. Hepatic resection is associated with tumor recurrence rates of up to 74 % at 5 years [
4]. Due to the most frequent cause of postoperative death among patients with HCC is tumor recurrence in the remnant liver, the long-term prognosis after hepatic resection remains unsatisfactory. Therefore, prevention of tumor recurrence via postoperative or adjuvant treatments is an important unmet clinical requirement in patients with HCC. Despite all this, no postoperative or adjuvant treatment is recommended by official guidelines until now [
5,
6]. …
